For small molecule targeted drugs (tsDMARDs), such as JAK inhibitors, although randomized controlled trials (RCTs) have demonstrated the short- to medium-term safety of JAK inhibitors, studies in RA patients with cardiovascular risk factors suggest that tofacitinib (a JAK inhibitor) is associated with a higher risk of malignancies and major adverse cardiovascular events (MACE) compared with TNF inhibitors. The gene discussed is TNF; the disease is rheumatoid arthritis.